Naoko Takebe to Disease Progression
This is a "connection" page, showing publications Naoko Takebe has written about Disease Progression.
Connection Strength
0.294
-
Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
Score: 0.129
-
Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients. Clin Cancer Res. 2004 Dec 15; 10(24):8301-8.
Score: 0.052
-
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
Score: 0.039
-
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2015; 56(12):3336-42.
Score: 0.027
-
Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 2015 Feb 06; 8:9.
Score: 0.026
-
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011 Dec; 74(3):481-5.
Score: 0.020